A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

计划入组 1,000 人 · 首次发布于 2021 年 4 月 19 日

Administration of Allogenic Red Blood Cells Loaded L-asparaginase in Cases of Relapse of Acute Lymphoblastic Leukaemia

计划入组 25 人 · 首次发布于 2008 年 7 月 28 日

International Multicenter Study of the Navitor/Navitor Vision Transcatheter Aortic Valve Platform

计划入组 1,000 人 · 首次发布于 2026 年 1 月 22 日

Avena sativa pollen

Lactuca sativa whole

Medicago sativa top

NATIVIS, INC.

United States

ALASKA NATIVE TRIBAL HEALTH CONSORTIUM

United States

NATUVA PTY LTD

Australia

Inventiva's Lanifibranor Maintains Positive Safety Profile in Phase 3 MASH Trial

Inventiva's Lanifibranor Maintains Positive Safety Profile in Phase 3 MASH Trial

Inventiva Secures €348 Million to Advance Phase 3 MASH Study of Lanifibranor